- Companies
- Aberdeen Group
Aberdeen Group Valuation Multiples
Aberdeen Group is valued at $5.3B as of November 2026, a 2.3x revenue multiple. In the last 12 months, Aberdeen Group revenue was $1.7B and Aberdeen Group EBITDA was $448M.
Aberdeen Group Overview
About Aberdeen Group
Aberdeen Group PLC provides a variety of investment services. It operates in the following segments: Adviser, Investments, and Other. The investments segment involves a asset management business that provides investment solutions for Institutional, Wholesale, and Insurance Partners clients. The Adviser business provides platform services to wealth managers and advisers along with the Group’s Managed Portfolio Service (MPS) business. The majority of the company's income comes from the United Kingdom.
Founded
2005
HQ
Employees
4.6K
Website
Sectors
Financials (LTM)
EV
$3.9B
Valuation Multiples
Start free trialAberdeen Group Financials
Aberdeen Group reported last 12-month revenue of $1.7B and EBITDA of $448M.
In the same LTM period, Aberdeen Group generated $1.3B in gross profit, $448M in EBITDA, and $383M in net income.
Revenue (LTM)
Aberdeen Group P&L
In the most recent fiscal year, Aberdeen Group reported revenue of $1.8B and EBITDA of $702M.
Aberdeen Group is profitable as of last fiscal year, with gross margin of 66%, EBITDA margin of 40%, and net margin of 30%.
Financial data powered by Morningstar, Inc.
Aberdeen Group Stock Performance
Aberdeen Group has current market cap of $5.3B, and enterprise value of $3.9B.
Market Cap Evolution
Aberdeen Group's stock price is $2.96.
Aberdeen Group share price increased by 7.8% in the last year.
Aberdeen Group has an EPS (earnings per share) of $0.29.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.9B | $5.3B | -1.9% | 0.0% | -13.5% | 7.8% | $0.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAberdeen Group Valuation Multiples
Aberdeen Group trades at 2.3x EV/Revenue multiple, and 8.7x EV/EBITDA.
EV / Revenue (LTM)
Aberdeen Group Financial Valuation Multiples
As of November 19, 2026, Aberdeen Group has market cap of $5.3B and EV of $3.9B.
Aberdeen Group has a P/E ratio of 13.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aberdeen Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Aberdeen Group Margins & Growth Rates
Aberdeen Group decreased revenue by 3% and EBITDA by 36% in the last fiscal year.
In the most recent fiscal year, Aberdeen Group reported gross margin of 66%, EBITDA margin of 40%, and net margin of 30%.
Aberdeen Group Margins
Aberdeen Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Aberdeen Group Operational KPIs
Aberdeen Group's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Aberdeen Group's Rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aberdeen Group's Rule of X is 20% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Aberdeen Group Competitors
Aberdeen Group competitors include Gecina, Main Street Capital, Sunshine Insurance Group, SWI Capital Holding, Covivio, Korea Investment Holdings, Challenger, Soochow Securities, Capital Securities Corp. and Azimut Group.
Most Aberdeen Group public comparables operate across Asset Management.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $944M | $606M | 13.5x | 16.1x | 21.0x | 19.4x | |||
| $720M | - | 10.7x | 13.4x | - | - | |||
| $14B | $1.5B | 0.4x | 0.4x | 3.6x | - | |||
| $103M | - | 68.4x | - | - | - | |||
| $1.5B | $1.5B | 13.5x | 27.1x | 14.1x | 29.0x | |||
| $3.7B | - | 1.5x | 1.4x | - | - | |||
| $2B | $487M | 2.7x | 8.3x | 11.1x | 12.0x | |||
| $1.3B | - | 4.0x | 3.9x | - | - | |||
This data is available for Pro users. Sign up to see all Aberdeen Group competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by Aberdeen Group
Aberdeen Group has acquired 24 companies to date.
Last acquisition by Aberdeen Group was on December 12th 2025. Aberdeen Group acquired MFS Intermediate IT for undisclosed valuation.
Latest Acquisitions by Aberdeen Group
| Description | MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors. | Tritax Group is a London-headquartered fund manager specializing in high-quality logistics real estate across Europe. The firm oversees investment vehicles including Tritax Big Box and Tritax EuroBox, targeting well-located warehouses for institutional investors. Tritax Group executes acquisitions, developments, and asset management in key logistics hubs. | Tekla Capital Management is a Boston-based registered investment adviser overseeing two closed-end funds, Tekla Healthcare Investors and Tekla Life Sciences Growth Fund. These funds target growth-oriented public and private equities in healthcare and life sciences sectors, including biotechnology, pharmaceuticals, and medical devices. With a focus on North American markets, the firm provides portfolio management and shareholder services from its Massachusetts headquarters. | Circuito Vial 3 is a road concession company that finances, builds, operates and maintains a 292 km section of Route 14 in Uruguay under a public-private partnership with the Ministry of Transport and Public Works. The concession covers four departments, was awarded in 2019 to Copasa and Espina Obras Hidraulicas for a 20-year term and is the largest highway concession in the country. Its customer is the Uruguayan state, which pays for availability and performance of the road rather than traffic volumes, so revenue is largely contracted. The company is a special-purpose project vehicle with no products beyond the concession, owned through the holding company Hareson Investments. It was acquired in 2023 by a consortium of abrdn and Bestinver, which bought 100% from the original contractors. | |
| HQ Country | |||||
| HQ City | Boston, MA | London | Boston, MA | - | |
| Deal Date | 12 Dec 2025 | 29 Oct 2025 | 20 Jun 2023 | 11 May 2023 | |
| Valuation | undisclosed | undisclosed | undisclosed | $228M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Aberdeen Group acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Aberdeen Group
Aberdeen Group has invested in 14 companies to date.
Latest investment by Aberdeen Group was on November 12th 2025. Aberdeen Group invested in FNZ in their $650M Undisclosed stage round (EV/Revenue multiple available to Pro users).
Latest Investments by Aberdeen Group
| Description | FNZ is a wealth management platform technology company headquartered in London. It provides banks, insurers, asset managers and wealth managers with an end-to-end platform covering client onboarding, financial planning, order execution, custody, settlement and portfolio administration, delivered as a long-term outsourced service rather than as licensed software alone. | Glycomine is a San Francisco-based early-stage biotechnology firm focused on enzyme replacement therapies for rare genetic disorders lacking approved treatments. Targeting the 95 percent of 7,000 known rare diseases without FDA options, it advances protein therapeutics to address unmet needs in metabolic and lysosomal storage conditions. | Atalanta Therapeutics is a biotechnology company developing RNA interference therapies for neurodegenerative diseases. Leveraging its proprietary RNA delivery platform, the firm targets ALS and Parkinson's, with preclinical programs silencing disease-causing genes in the central nervous system. Backed by ARCH Venture Partners, Atalanta operates from Boston. | Aviceda Therapeutics is a Boston-based clinical-stage biotechnology company developing glycan therapeutics for glyco-immune diseases. The firm targets chronic inflammation in areas like ophthalmology, fibrosis, neurology, and oncology with lead candidates AVD-104 for dry eye disease, AVD-302 for diabetic retinopathy, and AVD-401 for retinoblastoma. Aviceda employs proprietary podocyte technology and high-throughput screening to engineer multivalent glycan compounds that modulate innate immune cells. | |
| HQ Country | |||||
| HQ City | London | San Francisco, CA | Boston, MA | Boston, MA | |
| Deal Date | 12 Nov 2025 | 16 Apr 2025 | 28 Jan 2025 | 7 Jan 2025 | |
| Round | Undisclosed stage | Series C | Series B | Series C | |
| Raised | $650M | $115M | $97M | $208M | |
| Investors | La Caisse; Ninety One; Aviva; Motive Partners; Aberdeen Group; CPP Investments; Generation Investment Management; FirstCape; Nucleus Financial | Asahi Kasei Corporate Venture Capital; Novo Holdings; Chiesi Ventures; Aberdeen Group; Advent Life Sciences; Abingworth; CTI Life Sciences Fund; RiverVest; Sanderling Ventures; Sanofi Ventures; Remiges Ventures | Mirae Asset; Novartis Venture Fund; EQT; Aberdeen Group; F-Prime; RiverVest; Pictet Alternative Advisors; Sanofi Ventures; GHR Foundation | Digitalis Ventures; TCG Crossover; Blue Owl Capital Inc.; Marshall Wace; Aberdeen Group; Catalio Capital Management; Logos Capital; Omega Funds; Jeito Capital; Enavate Sciences; OrbiMed; Longitude Capital | |
| Valuation | $20B | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Aberdeen Group investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aberdeen Group
| When was Aberdeen Group founded? | Aberdeen Group was founded in 2005. |
| Where is Aberdeen Group headquartered? | Aberdeen Group is headquartered in United Kingdom. |
| How many employees does Aberdeen Group have? | As of today, Aberdeen Group has over 4K employees. |
| Who is the CEO of Aberdeen Group? | Aberdeen Group's CEO is Jason Michael Windsor. |
| Is Aberdeen Group publicly listed? | Yes, Aberdeen Group is a public company listed on London Stock Exchange. |
| What is the stock symbol of Aberdeen Group? | Aberdeen Group trades under ABDN ticker. |
| When did Aberdeen Group go public? | Aberdeen Group went public in 2006. |
| Who are competitors of Aberdeen Group? | Aberdeen Group main competitors include Gecina, Main Street Capital, Sunshine Insurance Group, SWI Capital Holding, Covivio, Korea Investment Holdings, Challenger, Soochow Securities, Capital Securities Corp., Azimut Group. |
| What is the current market cap of Aberdeen Group? | Aberdeen Group's current market cap is $5.3B. |
| What is the current revenue of Aberdeen Group? | Aberdeen Group's last 12 months revenue is $1.7B. |
| What is the current revenue growth of Aberdeen Group? | Aberdeen Group revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Aberdeen Group? | Current revenue multiple of Aberdeen Group is 2.3x. |
| What is the current EBITDA of Aberdeen Group? | Aberdeen Group's last 12 months EBITDA is $448M. |
| What is Aberdeen Group's EBITDA margin? | Aberdeen Group's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Aberdeen Group? | Current EBITDA multiple of Aberdeen Group is 8.7x. |
| What is the current FCF of Aberdeen Group? | Aberdeen Group's last 12 months FCF is $466M. |
| What is Aberdeen Group's FCF margin? | Aberdeen Group's last 12 months FCF margin is 27%. |
| What is the current EV/FCF multiple of Aberdeen Group? | Current FCF multiple of Aberdeen Group is 8.4x. |
| How many companies Aberdeen Group has acquired to date? | As of November 2026, Aberdeen Group has acquired 23 companies. |
| What was the largest acquisition by Aberdeen Group? | $4.7B acquisition of Aberdeen Asset Management on 6th March 2017 was the largest M&A Aberdeen Group has done to date. |
| What companies Aberdeen Group acquired? | Aberdeen Group acquired Aberdeen Asset Management, Interactive Investor, Circuito Vial 3, Finimize, AXA Portfolio Services, room2 hometels, Tritax Group, Hark Capital, Grant Thornton UK Wealth Advisory, Newton Private Clients, and 13 other companies. |
| In how many companies Aberdeen Group has invested to date? | As of November 2026, Aberdeen Group has invested in 14 companies. |
| What was the last Aberdeen Group investment? | On 12th November 2025 Aberdeen Group invested in FNZ, participating in a $650M Undisclosed stage round at $20B valuation, alongside La Caisse, Ninety One, Aviva, Motive Partners, CPP Investments, Generation Investment Management, FirstCape, and Nucleus Financial. |
| In what companies Aberdeen Group invested in? | Aberdeen Group invested in FNZ, Aviceda Therapeutics, Trinity Gas Storage, Engrail Therapeutics, Glycomine, Dott, Atalanta Therapeutics, Signal AI, Radiant Biotherapeutics, Archax, Qlaris Bio, Eagle Genomics, Singlife, and Nucoro. |
See public comps similar to Aberdeen Group
Lists including Aberdeen Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




